Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636269 · ClinicalTrials.gov registry record · Phase 3
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A Phase 3 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 473
- Enrollment target
NCT03636269 is a Phase 3 study that has completed, run by Cara Therapeutics. The registered enrollment target is 473 participants.
The verdict
NCT03636269, a Phase 3 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 473 participants
- Enrollment target
Study Summary
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.
Interventions
- DRUG Placebo
- DRUG CR845 0.5 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 473 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636269
The ClinicalTrials.gov registry entry for NCT03636269 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 473 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03636269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636269 about?
NCT03636269 is a clinical study titled "CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.
What is the current status of trial NCT03636269?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 473 participants. The study started on 2018-07-17. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT03636269?
The interventions under investigation include: Placebo (DRUG), CR845 0.5 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT03636269?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.